A detailed history of Sargent Investment Group, LLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Sargent Investment Group, LLC holds 21,460 shares of RLMD stock, worth $8,154. This represents 0.01% of its overall portfolio holdings.

Number of Shares
21,460
Previous 21,460 -0.0%
Holding current value
$8,154
Previous $64,000 7.81%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$2.93 - $4.94 $1,048 - $1,768
-358 Reduced 1.64%
21,460 $64,000
Q1 2024

May 10, 2024

BUY
$3.1 - $6.8 $67,635 - $148,362
21,818 New
21,818 $101,000
Q3 2023

Nov 13, 2023

SELL
$2.48 - $3.79 $744 - $1,137
-300 Reduced 1.82%
16,206 $48,000
Q2 2023

Jul 31, 2023

BUY
$2.22 - $3.54 $4,859 - $7,749
2,189 Added 15.29%
16,506 $40,000
Q1 2023

May 02, 2023

BUY
$2.24 - $4.76 $32,070 - $68,148
14,317 New
14,317 $32,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $10.9M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Sargent Investment Group, LLC Portfolio

Follow Sargent Investment Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Investment Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Investment Group, LLC with notifications on news.